Potential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness: A Critical Connection to Nitric Oxide Levels and PARP Activity

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Ibba, Salome V ^a,b   Ghonim, Mohamed A ^a,c   Pyakurel, Kusma ^a   Lammi, Matthew R ^a   Mishra, Anil ^d   Boulares, A Hamid ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c Al Azhar University   (Egypt)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OLAPARIB; OVALBUMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE SYNTHASE; NITRITE; NITROGEN OXIDE; PARP1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CELL ACTIVATION; CONTROLLED STUDY; DERMATOPHAGOIDES; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NITRATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ALLERGENS; ANIMALS; ASTHMA; CELLS, CULTURED; HUMANS; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; NITROGEN OXIDES; POLY (ADP-RIBOSE) POLYMERASE-1; RESPIRATORY HYPERSENSITIVITY; SIGNAL TRANSDUCTION;

EID: 84982793319     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/1984703     Document Type: Article

References (37)

1. R. H. Moreno, J. C. Hogg, and P. D. Pare, "Mechanics of airway narrowing, " American Review of Respiratory Disease, vol. 133, no. 6, pp. 1171-1180, 1986.
2. Y. Bossé, P. D. Paré, and C. Y. Seow, "Airway wall remodeling in asthma: from the epithelial layer to the adventitia, " Current Allergy and Asthma Reports, vol. 8, no. 4, pp. 357-366, 2008.
3. R. Halwani, S. Al-Muhsen, and Q. Hamid, "Airway remodeling in asthma, " Current Opinion in Pharmacology, vol. 10, no. 3, pp. 236-245, 2010.
4. H. S. Park, S. Y. Kim, S. R. Kim, and Y. C. Lee, "Targeting abnormal airway vascularity as a therapeutical strategy in asthma, " Respirology, vol. 15, no. 3, pp. 459-471, 2010.
5. C. B. Barnes and C. S. Ulrik, "Asthma and adherence to inhaled corticosteroids: current status and future perspectives, " Respiratory Care, vol. 60, no. 3, pp. 455-468, 2015.
6. B. N. Lambrecht and H. Hammad, "The immunology of asthma, " Nature Immunology, vol. 16, no. 1, pp. 45-56, 2015.
7. L. R. DeNicola, N. Kissoon, L. J. Duckworth, K. V. Blake, S. P. Murphy, and P. E. Silkoff, "Exhaled nitric oxide as an indicator of severity of asthmatic inflammation, " Pediatric Emergency Care, vol. 16, no. 4, pp. 290-295, 2000.
8. F. L. M. Ricciardolo, F. P. Nijkamp, and G. Folkerts, "Nitric Oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease, " Current Drug Targets, vol. 7, no. 6, pp. 721-735, 2006.
9. P. Kirkham and I. Rahman, "Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy, " Pharmacology andTherapeutics, vol. 111, no. 2, pp. 476-494, 2006.
10. W. MacNee, "Oxidative stress and lung inflammation in airways disease, " European Journal of Pharmacology, vol. 429, no. 1-3, pp. 195-207, 2001.
11. J. S. Beckman, "Understanding peroxynitrite biochemistry and its potential for treating human diseases, " Archives of Biochemistry and Biophysics, vol. 484, no. 2, pp. 114-116, 2009.
12. H. Sugiura and M. Ichinose, "Oxidative and nitrative stress in bronchial asthma, " Antioxidants and Redox Signaling, vol. 10, no. 4, pp. 785-797, 2008.
13. M. Yamamoto, Y. Tochino, K. Chibana, J. B. Trudeau, F. Holguin, and S. E. Wenzel, "Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation, " Clinical and Experimental Allergy, vol. 42, no. 5, pp. 760-768, 2012.
14. T. T. Hansel, S. A. Kharitonov, L. E. Donnelly et al., "Aselective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics, " The FASEB Journal, vol. 17, no. 10, pp. 1298-1300, 2003.
15. S. A. Mulrennan and A. E. Redington, "Nitric oxide synthase inhibition: therapeutic potential in asthma, " Treatments in Respiratory Medicine, vol. 3, no. 2, pp. 79-88, 2004.
16. C. Brindicci, K. Ito, P. J. Barnes, and S. A. Kharitonov, "Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers, " Chest, vol. 132, no. 2, pp. 581-588, 2007.
17. D. Singh, D. Richards, R. G. Knowles et al., "Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma, " American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 10, pp. 988-993, 2007.
18. T. Islam, C. Breton, M. T. Salam et al., "Role of inducible nitric oxide synthase in asthma risk and lung function growth during adolescence, " Thorax, vol. 65, no. 2, pp. 139-145, 2010.
19. A. S. Naura, M. Zerfaoui, H. Kim et al., "Requirement for inducible nitric oxide synthase in chronic allergen exposureinduced pulmonary fibrosis but not inflammation, " Journal of Immunology, vol. 185, no. 5, pp. 3076-3085, 2010.
20. A. S. Naura, R. Datta, C. P. Hans et al., "Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia, " European Respiratory Journal, vol. 33, no. 2, pp. 252-261, 2009.
21. M. A. Ghonim, K. Pyakurel, S. V. Ibba et al., "PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice, " Clinical Science (London, England), vol. 129, no. 11, pp. 951-962, 2015.
22. M. A. Ghonim, K. Pyakurel, S. V. Ibba et al., "PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function, " Journal of Translational Medicine, vol. 13, no. 1, article 225, 2015.
23. R. A. Nathan, C. A. Sorkness, M. Kosinski et al., "Development of the asthma control test: a survey for assessing asthma control, " Journal of Allergy andClinical Immunology, vol. 113, no. 1, pp. 59-65, 2004.
24. J. Bousquet, P. K. Jeffery, W. W. Busse, M. Johnson, and A. M. Vignola, "Asthma: from bronchoconstriction to airways inflammation and remodeling, "American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 5, pp. 1720-1745, 2000.
25. W. M. Moore, R. K. Webber, G. M. Jerome, F. S. Tjoeng, T. P. Misko, and M. G. Currie, "L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase, " Journal of Medicinal Chemistry, vol. 37, no. 23, pp. 3886-3888, 1994.
26. K. Cosby, K. S. Partovi, J. H. Crawford et al., "Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation, " Nature Medicine, vol. 9, no. 12, pp. 1498-1505, 2003.
27. C. Gerard, "Asthmatics breathe easier when it's SNO-ing, " Science, vol. 308, no. 5728, pp. 1560-1561, 2005.
28. C. Lane, D. Knight, S. Burgess et al., "Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath, " Thorax, vol. 59, no. 9, pp. 757-760, 2004.
29. H. Sugiura, Y. Komaki, A. Koarai, and M. Ichinose, "Nitrative stress in refractory asthma, " Journal of Allergy and Clinical Immunology, vol. 121, no. 2, pp. 355-360, 2008.
30. N. Voraphani, M. T. Gladwin, A. U. Contreras et al., "An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2 nitrative stress in human severe asthma, " Mucosal Immunology, vol. 7, no. 5, pp. 1175-1185, 2014.
31. W. W. Busse, "The relationship of airway hyperresponsiveness and airway inflammation: airway hyperresponsiveness in asthma: its measurement and clinical significance, " Chest, vol. 138, no. 2, supplement, pp. 4S-10S, 2010.
32. M. R. Duranski, J. J. M. Greer, A. Dejamet al., "Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver, "The Journal of Clinical Investigation, vol. 115, no. 5, pp. 1232-1240, 2005.
33. J. Hamacher, K. Eichert, C. Braun et al., "Montelukast exerts no acute direct effect on NO synthases, " Pulmonary Pharmacology andTherapeutics, vol. 20, no. 5, pp. 525-533, 2007.
34. A. S. Naura, C. P. Hans, M. Zerfaoui et al., "Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation, " Clinical and Experimental Allergy, vol. 38, no. 5, pp. 839-846, 2008.
35. E. Hamelmann, J. Schwarze, K. Takeda et al., "Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography, " American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 3, pp. 766-775, 1997.
36. M. Zerfaoui, Y. Errami, A. S. Naura et al., "Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65NF-B uponTLR4 stimulation, "The Journal of Immunology, vol. 185, no. 3, pp. 1894-1902, 2010.
37. R. A. Dweik, P. B. Boggs, S. C. Erzurum et al., "An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications, " American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 5, pp. 602-615, 2011.